- The Wall Street Journal•17 hours ago
After drawing venture investors and collaborator Takeda Pharmaceutical Co. to an early-stage technology for precisely targeted cancer drugs to tumors, Mersana is poised to find out how well this approach ...
- Moody's•5 days agoAstellas Pharma Inc. -- Moody's: Japanese pharmaceutical companies' expiring drugs patents could prompt strategic alliances
Tokyo, October 20, 2016-- Moody's Japan K.K. says that the expiry of key drug patents over the next 1-3 years will pressure the revenues of the rated Japanese pharmaceutical companies, and could prompt ...
- PR Newswire•8 days agoTakeda Presents Real-World Vedolizumab Data in Ulcerative Colitis and Crohn's Disease at 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting
DEERFIELD, Ill., Oct. 17, 2016 /PRNewswire/ -- Today, Takeda Pharmaceuticals U.S.A., Inc. ("Takeda"), announced data highlighting the effectiveness and safety profile of vedolizumab for the treatment ...
Takeda Pharmaceutical Company Limited (TKPYY)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||22.52 - 22.53|
|52wk Range||20.32 - 25.72|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||23.64|
|Avg Vol (3m)||30,323|
|Dividend & Yield||0.87 (3.83%)|